166 related articles for article (PubMed ID: 20731681)
1. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
Abbate I; Rozera G; Tommasi C; Bruselles A; Bartolini B; Chillemi G; Nicastri E; Narciso P; Ippolito G; Capobianchi MR
Clin Microbiol Infect; 2011 May; 17(5):725-31. PubMed ID: 20731681
[TBL] [Abstract][Full Text] [Related]
2. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
4. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G; Abbate I; Giombini E; Castagna A; De Luca A; Ceccherini-Silberstein F; Cozzi Lepri A; Cassola G; Torti C; d'Arminio Monforte A; Ippolito G; Capobianchi MR;
J Antimicrob Chemother; 2014 Nov; 69(11):3085-94. PubMed ID: 25015667
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two genotypic algorithms to determine HIV-1 tropism.
Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
[TBL] [Abstract][Full Text] [Related]
8. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
9. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.
Low AJ; Dong W; Chan D; Sing T; Swanstrom R; Jensen M; Pillai S; Good B; Harrigan PR
AIDS; 2007 Sep; 21(14):F17-24. PubMed ID: 17721088
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
11. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
[TBL] [Abstract][Full Text] [Related]
12. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
Rodriguez C; Soulié C; Marcelin AG; Calvez V; Descamps D; Charpentier C; Flandre P; Recordon-Pinson P; Bellecave P; Pawlotsky JM; Masquelier B;
PLoS One; 2015; 10(6):e0127816. PubMed ID: 26068869
[TBL] [Abstract][Full Text] [Related]
15. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
Gupta S; Neogi U; Srinivasa H; Shet A
J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
[TBL] [Abstract][Full Text] [Related]
16. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
17. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.
Poveda E; Seclén E; González Mdel M; García F; Chueca N; Aguilera A; Rodríguez JJ; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2009 May; 63(5):1006-10. PubMed ID: 19261623
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
